The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospective study
暂无分享，去创建一个
G. Marcucci | S. Forman | R. Nakamura | S. Dadwal | H. Ali | Shukaib Arslan | M. A. Al Malki | A. Aribi | Dat Ngo | Jason Chen | Jose Tinajero
[1] A. Kassim,et al. SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies , 2022, Blood Reviews.
[2] D. Couriel,et al. Chronic graft-versus-host disease exacerbation after SARS-CoV-2 vaccination , 2022, Bone Marrow Transplantation.
[3] Michael I. Mandel,et al. Waning Immunity after the BNT162b2 Vaccine in Israel , 2021, The New England journal of medicine.
[4] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months , 2021, The New England journal of medicine.
[5] G. Marcucci,et al. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients , 2021, Transplantation and Cellular Therapy.
[6] J. Warner,et al. Care without a compass: Including patients with cancer in COVID-19 studies , 2021, Cancer Cell.
[7] M. Perales,et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study , 2021, The Lancet Haematology.
[8] Stephanie J. Lee. Classification systems for chronic graft-versus-host disease. , 2017, Blood.
[9] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..